Payment overview · 2025
General Payments
$2,631.87
124 reported records · 28 companies
Healthcare provider profile · identity verified
Ali Emami, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · MILTON, MA · NPI 1992767966
Verified facts
What the public records show
CMS Open Payments records show Ali Emami, M.D. received $2,631.87 in general payments during 2025 across 124 reported records.
Lilly USA, LLC accounted for 12.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Lokelma by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexlizet by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $322.26 | 12.2% | 13 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $246.01 | 9.3% | 12 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $182.38 | 6.9% | 10 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $165.31 | 6.3% | 7 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $164.65 | 6.3% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $161.41 | 6.1% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $152.67 | 5.8% | 7 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $149.31 | 5.7% | 9 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$120.15 | 4.6% | 5 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $102.17 | 3.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $82.19 | 3.1% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $78.52 | 3.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $75.03 | 2.9% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $70.89 | 2.7% | 4 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $70.61 | 2.7% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $67.80 | 2.6% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $56.89 | 2.2% | 2 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $55.88 | 2.1% | 8 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $45.33 | 1.7% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.63 | 1.7% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $39.89 | 1.5% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $39.44 | 1.5% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $34.65 | 1.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $24.87 | 0.9% | 1 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $22.89 | 0.9% | 1 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $22.54 | 0.9% | 1 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $18.75 | 0.7% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $14.75 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,599.25 | 117 |
| Education | $32.62 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $395.67 | 16 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $182.38 | 10 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $165.31 | 7 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $149.31 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $136.12 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $126.41 | 6 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $119.60 | 6 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $107.85 | 5 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $102.17 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $79.26 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $79.26 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $78.52 | 3 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $74.08 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $70.89 | 4 | 2025 |
Source payment records
|
|||||
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $70.61 | 4 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $65.01 | 3 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $56.89 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $56.80 | 3 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $46.07 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $46.05 | 2 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $45.33 | 2 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $44.63 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $44.49 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $41.89 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $39.89 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $39.44 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $34.65 | 2 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $33.14 | 1 | 2025 |
Source payment records
|
|||||
| Filspari Normalized: filspari |
Drug | Travere Therapeutics, Inc. | $32.62 | 7 | 2025 |
Source payment records
|
|||||
| Vanrafia Normalized: vanrafia |
Drug | Novartis Pharmaceuticals Corporation | $30.35 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $25.29 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.31 | 1 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $22.89 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $22.89 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $22.89 | 1 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $22.54 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.43 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $14.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 51 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
70 | 24 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 274 | 85 |
| Losartan Potassium | Losartan Potassium | 205 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 163 | 51 |
| Allopurinol | Allopurinol | 139 | 41 |
| Labetalol Hcl | Labetalol Hcl | 132 | 42 |
| Metformin Hcl | Metformin Hcl | 103 | 32 |
| Levothyroxine Sodium | Levothyroxine Sodium | 75 | 22 |
| Simvastatin | Simvastatin | 75 | 19 |
| Lisinopril | Lisinopril | 73 | 20 |
| Lokelma | Sodium Zirconium Cyclosilicate | 70 | 24 |
| Omeprazole | Omeprazole | 68 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 58 | 18 |
| Jardiance | Empagliflozin | 51 | 12 |
| Metoprolol Succinate | Metoprolol Succinate | 51 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 48 | 15 |
| Furosemide | Furosemide | 44 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | 11 |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Torsemide | Torsemide | 34 | 11 |
| Eliquis | Apixaban | 32 | suppressed |
| Irbesartan | Irbesartan | 29 | suppressed |
| Lactulose | Lactulose | 29 | 13 |
| Repatha Sureclick | Evolocumab | 29 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 29 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 18 |
| Finasteride | Finasteride | 26 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 24 | suppressed |
| Gabapentin | Gabapentin | 21 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Potassium Chloride | Potassium Chloride | 16 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 12 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Carvedilol | Carvedilol | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,631.87 · 124 records | Lilly USA, LLC | AREXVY, BENLYSTA, CeQur Simplicity, Cologuard Collection Kit, EVENITY, FUROSCIX, Fabhalta, Filspari, GVOKE HYPOPEN, IBSRELA, INTELLIS ADAPTIVESTIM, JARDIANCE, JATENZO, Kerendia, MINIMED 780G, MOUNJARO, NEXLETOL, Omnipod, Ozempic, PROLIA, Paradise Ultrasound Renal Denervation System, RECORLEV, REPATHA, Rybelsus, SHINGRIX, STRENSIQ, SYNTHROID, TZIELD, The Cologuard Plus Collection Kit, Vanrafia, Veltassa, Veozah, Wegovy, XYOSTED, Yorvipath, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset, t:slim X2 Insulin Pump with Control-IQ | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error